 |
|
1-888-632-5353
M-F 8 AM - 9 PM EST
|
|
is Searching for
Plans in ZIP Code
|
Sorry, that ZIP code
was not found.
Try Again
|
|
|
is Searching for
Dentist in ZIP Code
|
|
|
|
you are here: DentalPlans.com > Dental Health Articles > HealthnewsDigest.com > The Acetaminophen Challenge and Recommendations
| |
|
|
|
Updated: 7/7/2009 7:00:31 PM |
|
|
(HealthNewsDigest.com) - Acetaminophen is the most widely used medication in the United States, being used by approximately 100 million people. Often designated by its most popular brand name Tylenol or as APAP (the abbreviation for its chemical name), it is supplied as a single active ingredient in numerous products, and with one or more other active ingredients in hundreds of combination products. There are valid reasons for the extensive use of acetaminophen. It is effective in relieving mild to moderate pain and relieving fever, and, when used in the recommended dosage, is one of the safest, if not the safest medication available. Its safety justifies its availability without a prescription.
The Problems
The maximum recommended adult dosage of acetaminophen is 4000 milligrams a day (in divided doses). When used in amounts that exceed this dosage, it may cause hepatic toxicity, and acetaminophen overdosage is the most frequent cause of liver failure in the U.S. Acetaminophen overdoses are responsible for an estimated 56,000 visits to emergency departments each year, and approximately 100 people die each year from accidental overdoses (as distinct from intentional overdoses [i.e., suicide attempts]). An estimated 60% of acetaminophen-related deaths have involved the use of prescription combination products such as Percocet (acetaminophen and oxycodone) and Vicodin (acetaminophen and hydrocodone). With these products, as well as with the nonprescription combination products used for conditions such as pain and colds, patients are often not aware that acetaminophen is one of the active ingredients. This is particularly true with the prescription opioid/acetaminophen combinations for which the primary attention and warnings focus on the more potent opioid component. Many of the accidental overdoses result from the use of two or more acetaminophen-containing products.
Failures to reduce the problems
The problems associated with acetaminophen overdosage have been recognized for many years. Warnings in the labeling and packages of the products have been strengthened, a public awareness campaign has been conducted, symposia have been held, and health professionals have been urged to be more diligent in monitoring for situations that could result in overdosage. However, hospitalizations for acetaminophen overdosage have not decreased. Although many patients have not demonstrated responsibility in knowing what medications they are taking and the precautions associated with their use, a large part of the responsibility for the failure to be more effective in preventing acetaminophen-associated problems rests with the companies marketing the products, health professionals, and the Food and Drug Administration (FDA). It was with this recognition that the FDA convened 37 health professionals who serve on three of its advisory committees (Drug Safety and Risk Management; Nonprescription Drugs; and Anesthetic and Life Support Drugs) to meet on June 29 and 30 for the purpose of recommending ways through which acetaminophen overdosages could be reduced.
Recommendations
Although the FDA is not required to accept the recommendations of its advisory committees, it usually does so. The joint advisory committee developed a number of recommendations at the end of its two-day meeting although it is noteworthy that the vote on certain of the recommendations was very close. The most important of these recommendations are identified below followed by my editorial comment/recommendation.
1. The committee recommended (by a vote of 21 to 16) that the FDA reduce the maximum daily dosage of acetaminophen from its current level of 4000 mg a day (for adults). A specific dosage to which it should be reduced was not specified although other committee recommendations suggest support for a maximum nonprescription dosage of 2600 mg a day (i.e., 650 mg four times a day).
I do not agree with this recommendation. There has been extensive experience with the current dosage recommendation and the safety record of the drug when used within these dosage parameters has been exceptionally good. The potential disadvantage of using acetaminophen in a lower dosage is that patients will not experience adequate/complete relief of pain. In view of the experience of the vast majority of patients who have used acetaminophen that the drug is both effective and safe in its currently recommended dosage, I anticipate that a recommendation to use a lower dosage will be widely ignored.
2. The committee recommended (by a vote of 24 to 13) that the single, nonprescription adult dose be reduced to 650 mg (from 1000 mg).
I do not agree with this recommendation. Many individuals do not use acetaminophen on a continuing basis but, rather, use one or two doses for the treatment of conditions such as headache. Although some will suggest that a dose of 650 mg will be sufficient to relieve pain, experience and reason suggest that a dose of 1000 mg will be more effective in relieving pain. The committee’s recommendation also has the potential to invite the development of an immediate-release tablet formulation that contains 650 mg of acetaminophen. Such a formulation might be confused with the controlled-release formulation of the same potency that is currently available.
Although I disagree with the committee’s recommendation, I do support the initial use of a dose of 500 mg (rather than 1000 mg that is recommended for some products) that may be subsequently increased to 1000 mg if the relief of pain is not adequate.
3. The committee recommended (by a vote of 26 to 11) that the current maximum single dose of 1000 mg (2 x 500 mg) be available only on prescription.
I do not agree with this recommendation. This recommendation recognizes the validity of single doses of 1000 mg of acetaminophen (as addressed in my comment in #2 above), but would limit such a dose to prescription use. A quantity of 1000 mg of any medication would result in a tablet formulation that is large in size and possibly difficult to swallow, particularly for the elderly. Therefore, this dose would most likely be provided by taking two tablets of a 500 mg-potency. This situation could create confusion for patients as to why they must have a prescription for 500 mg tablets when the recommended single dose for nonprescription use is 650 mg. It is also difficult to imagine that patients will be pleased with a prescription for acetaminophen as an outcome of a physician visit when they could have purchased the medication without a prescription. If the 500 mg tablets are no longer available on a nonprescription basis, a dose of 1000 mg can be approximated with the use of three 325 mg tablets.
4. The committee recommended (by a vote of 36 to 1) that there be only one concentration of nonprescription acetaminophen liquids for pediatric patients. However, some committee members thought that the one concentration should be the more concentrated formulation for infants whereas others thought that it should be the less concentrated formulation for older children.
I agree with this recommendation. Confusion regarding the two concentrations of the liquid formulations that are currently available has resulted in the administration of overdoses to children. I recommend that the single concentration be the less concentrated formulation although I sympathize with the parents having the challenge of administering a larger amount of liquid to a young child.
5. The committee recommended (by a vote of 20 to 17) that the FDA eliminate prescription acetaminophen combination products (e.g., Percocet, Vicodin).
I do not agree with this recommendation.
© 2009 HealthnewsDigest.com
|
|
|
|
|
|
|
|
The materials and articles published on DentalPlans.com are for informational purposes only. Although DentalPlans.com strives to be accurate and complete, the information is provided without liability for errors. DentalPlans.com does not warrant the accuracy or completeness of the information, text graphics, links, or other items contained on DentalPlans.com.
DentalPlans.com expressly disclaims liability for errors or omissions in these materials and DentalPlans.com makes no commitment to update the information on DentalPlans.com.
DentalPlans.com expressly disclaims all liability for the use or interpretation by others of information on DentalPlans.com. Decisions based on information contained on DentalPlans.com are the sole responsibility of the visitors, and visitors agree to hold DentalPlans.com and its Affiliates harmless against any claims for damages arising from decisions visitors make on such information.
Nothing on DentalPlans.com constitutes medical advice or other forms of advice. DentalPlans.com assumes no responsibility for material created or published by third parties linked to DentalPlans.com with or without DentalPlans.coms knowledge.
|
|
| |
|
Terms of Use | Privacy Policy | Site Map | Newsletter | Info to Go |
DP Goes Green |
Affiliate Program | Contact Us
|
The DENTALPLANS.COM website is administered by DENTALPLANS.COM, INC., a licensed Florida Discount Medical Plan Organization, 8100 S.W. 10th Street Suite #2000, Plantation, FL 33324. Plans and Programs offered by DentalPlans.com are not health insurance policies. Plans and Programs offered by DentalPlans.com provide discounts at certain health care providers for medical services. Plans and Programs offered by DentalPlans.com do not make payments directly to the providers of medical services. The Plan or Program member is obligated to pay for all health care services but will receive a discount from those health care providers who have contracted with the Plan, Program or discount plan organization.
© 1999-2010 DentalPlans.com, Inc. All Rights Reserved. Patents Pending. |
   |
|
| |
|  |
|